Media Spotlight
PC3I Director Justin Bekelman, Advisory group member Amol Navathe, and Affiliate Atul Gupta, along with their coauthors, have completed the first study to demonstrate how a national insurer’s voluntary pay-for-performance (P4P) program can successfully incentivize oncologists to change their prescribing behavior to deliver higher-quality cancer care. A P4P program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care.
“We know that prescribing evidence-based cancer drugs is high-quality care and increases both the length and quality of life for patients with cancer,” said Dr. Bekelman. “And yet, changing prescribing patterns has been and remains a big challenge. Based on what we found here, paying oncology practices to prescribe evidence-based drugs can serve as a valuable tactic to improve the quality of cancer care.”
Informing policy-makers on researched-based, innovative cancer care solutions is core to PC3I’s mission to improve cancer care. The study has been covered in several outlets, including DocWireNews, ScienMag, Medical Xpress, News Medical, and more. Click here to read the full news release.
Related News
Media Spotlight
PC3I Associate Director Lola Fayanju on Breast Cancer Screening Recommendations
09.27.2023
In an interview with the Philadelphia Inquirer, PC3I Associate Director Lola Fayanju commented on recently updated breast cancer screening recommendations.
Media Spotlight
Proton Therapy Study at Penn Medicine Gains New Attention
02.14.2023
As part of the RadComp study, Penn Medicine and over 20 radiation centers nationwide are comparing the effectiveness of photon therapy and proton therapy to treat breast cancer.
Media Spotlight
Machine Learning-Triggered Behavioral Nudges Quadrupled Serious Illness Conversation Rates
01.12.2023
A team led by PC3I Innovation Faculty Ravi Parikh has found that machine learning-triggered behavioral nudges quadrupled the rates of seriousness illness conversations for patients with advance cancer.